Endless schreef op 5 februari 2020 06:19:
So maybe I'll kick it off, Umer, with your first part of your question. So, specific to filgotinib, I think that you're right. Obviously, we are very well aware that it's going to be a very competitive environment. There's no doubt about that. But, I think we're being really smart about it. And what I mean by that is because I think what we're thinking about is making sure we're going to bring focus to the table. So, we’re going to be -- we are very clear about where we want to play, and where we play, we win. And that's about commercial excellence and medical excellence, to be honest with you. Because medical and commercial are going to need to partner very closely and we are already around the clinical data and the profile of this compound, and how that really needs to be at the center of everything we do with filgotinib.
Dit zijn stukjes uit de webcast betreffende Filgotinib, wordt wel heel belangrijk voor Gilead en.nog groot enthousiasme voor Galapagos